Brief: Mindmed Announces First Patient Dosed In Phase 3 Voyage Study Of Mm120 In Generalized Anxiety Disorder (Gad)

Definium Therapeutics

16/12/2024 12:36

Dec 16 (Reuters) - Mind Medicine (MindMed) Inc  MNMD.O :
    * MINDMED ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 VOYAGE
STUDY OF
MM120 IN GENERALIZED ANXIETY DISORDER (GAD)
    * MIND MEDICINE (MINDMED) INC - PANORAMA STUDY TO INITIATE
IN U.S.
AND EUROPE IN FIRST HALF OF 2025
    * MIND MEDICINE (MINDMED) INC - TOPLINE DATA FROM 12-WEEK
DOUBLE-BLIND PERIOD EXPECTED IN FIRST HALF OF 2026

Source text:  ID:nBw1rjHYYa 
Further company coverage:  MNMD.O